FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904186698> ?p ?o ?g. }

• W2904186698 endingPage "2032" @default.
• W2904186698 startingPage "2024" @default.
• W2904186698 abstract "Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss. Evidence supporting its efficacy in surgery for adolescent idiopathic scoliosis is not robust. This trial was designed to validate the clinical efficacy of TXA in surgery for adolescent idiopathic scoliosis.This institutional review board-approved prospective double-blinded trial involved 111 patients with adolescent idiopathic scoliosis who were randomized to receive either a placebo or TXA (50-mg/kg loading dose and 10-mg/kg/h infusion). Power analysis indicated that 50 patients per group would provide power to detect a >20% difference in blood loss. Two-way analysis of variance (ANOVA) was applied to compare blood loss rates (slopes) using the group-by-time interaction F test.The risk of clinically relevant blood loss (>20 mL/kg) was more than twice as high in the placebo group than in the TXA group (44% versus 21%, relative risk = 2.1, 95% confidence interval = 1.2 to 3.7). Compared with the placebo group, the TXA group had a 27% reduction in intraoperative blood loss, a significantly lower rate of intraoperative bleeding per hour (mean and standard deviation, 190 ± 73 versus 230 ± 80 mL, p = 0.01; F = 9.77, p < 0.001) and per fused spinal level (82 ± 32 versus 110 ± 40 mL, p < 0.001), less intraoperative blood loss (836 ± 373 versus 1,031 ± 484 mL, p = 0.02), and less postoperative bleeding (in the drain) (498 ± 228 versus 645 ± 318 mL, p = 0.009). Six patients who received a placebo and no patient who received TXA required an allogenic blood transfusion. No perioperative adverse events, including thromboembolic events or seizures, were observed. Three independent factors were predictive of blood loss: TXA administration, duration of surgery, and number of levels fused. Greater intraoperative blood loss was the only independent variable predictive of a longer hospital stay.Use of TXA in patients undergoing surgery for adolescent idiopathic scoliosis significantly reduced blood loss, by 27%, compared with that in the placebo group. The rate of intraoperative blood loss per hour and per level fused and the amount of postoperative blood loss were significantly lower in the TXA group. More placebo-treated patients received allogenic blood. Patients with greater intraoperative blood loss spent a longer time in the hospital.Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence." @default.
• W2904186698 created "2018-12-22" @default.
• W2904186698 creator A5002804310 @default.
• W2904186698 creator A5008709608 @default.
• W2904186698 creator A5008769882 @default.
• W2904186698 creator A5026878206 @default.
• W2904186698 creator A5029802394 @default.
• W2904186698 creator A5032282324 @default.
• W2904186698 creator A5051188293 @default.
• W2904186698 creator A5059205656 @default.
• W2904186698 creator A5060762339 @default.
• W2904186698 creator A5076334273 @default.
• W2904186698 date "2018-12-05" @default.
• W2904186698 modified "2023-10-14" @default.
• W2904186698 title "Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery" @default.
• W2904186698 cites W1571490772 @default.
• W2904186698 cites W1838035547 @default.
• W2904186698 cites W1948289543 @default.
• W2904186698 cites W1968549988 @default.
• W2904186698 cites W1969118658 @default.
• W2904186698 cites W1980365844 @default.
• W2904186698 cites W1985810044 @default.
• W2904186698 cites W1992332433 @default.
• W2904186698 cites W2005132794 @default.
• W2904186698 cites W2016016217 @default.
• W2904186698 cites W2019222462 @default.
• W2904186698 cites W2035092024 @default.
• W2904186698 cites W2042598817 @default.
• W2904186698 cites W2067947964 @default.
• W2904186698 cites W2083669022 @default.
• W2904186698 cites W2113694205 @default.
• W2904186698 cites W2117953661 @default.
• W2904186698 cites W2138122479 @default.
• W2904186698 cites W2153717258 @default.
• W2904186698 cites W2162249417 @default.
• W2904186698 cites W2174657578 @default.
• W2904186698 cites W2236130351 @default.
• W2904186698 cites W2275919127 @default.
• W2904186698 cites W2320956823 @default.
• W2904186698 cites W2320972450 @default.
• W2904186698 cites W2342865736 @default.
• W2904186698 cites W2464989644 @default.
• W2904186698 cites W2495481412 @default.
• W2904186698 cites W2539290297 @default.
• W2904186698 cites W2588642758 @default.
• W2904186698 cites W2607870311 @default.
• W2904186698 cites W4211098689 @default.
• W2904186698 cites W4232202937 @default.
• W2904186698 cites W4362038800 @default.
• W2904186698 doi "https://doi.org/10.2106/jbjs.18.00314" @default.
• W2904186698 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30516625" @default.
• W2904186698 hasPublicationYear "2018" @default.
• W2904186698 type Work @default.
• W2904186698 sameAs 2904186698 @default.
• W2904186698 citedByCount "63" @default.
• W2904186698 countsByYear W29041866982019 @default.
• W2904186698 countsByYear W29041866982020 @default.
• W2904186698 countsByYear W29041866982021 @default.
• W2904186698 countsByYear W29041866982022 @default.
• W2904186698 countsByYear W29041866982023 @default.
• W2904186698 crossrefType "journal-article" @default.
• W2904186698 hasAuthorship W2904186698A5002804310 @default.
• W2904186698 hasAuthorship W2904186698A5008709608 @default.
• W2904186698 hasAuthorship W2904186698A5008769882 @default.
• W2904186698 hasAuthorship W2904186698A5026878206 @default.
• W2904186698 hasAuthorship W2904186698A5029802394 @default.
• W2904186698 hasAuthorship W2904186698A5032282324 @default.
• W2904186698 hasAuthorship W2904186698A5051188293 @default.
• W2904186698 hasAuthorship W2904186698A5059205656 @default.
• W2904186698 hasAuthorship W2904186698A5060762339 @default.
• W2904186698 hasAuthorship W2904186698A5076334273 @default.
• W2904186698 hasConcept C126322002 @default.
• W2904186698 hasConcept C141071460 @default.
• W2904186698 hasConcept C142724271 @default.
• W2904186698 hasConcept C168563851 @default.
• W2904186698 hasConcept C204787440 @default.
• W2904186698 hasConcept C27081682 @default.
• W2904186698 hasConcept C2779637338 @default.
• W2904186698 hasConcept C2780955175 @default.
• W2904186698 hasConcept C2781436528 @default.
• W2904186698 hasConcept C2991743468 @default.
• W2904186698 hasConcept C2993634128 @default.
• W2904186698 hasConcept C42219234 @default.
• W2904186698 hasConcept C44249647 @default.
• W2904186698 hasConcept C71924100 @default.
• W2904186698 hasConceptScore W2904186698C126322002 @default.
• W2904186698 hasConceptScore W2904186698C141071460 @default.
• W2904186698 hasConceptScore W2904186698C142724271 @default.
• W2904186698 hasConceptScore W2904186698C168563851 @default.
• W2904186698 hasConceptScore W2904186698C204787440 @default.
• W2904186698 hasConceptScore W2904186698C27081682 @default.
• W2904186698 hasConceptScore W2904186698C2779637338 @default.
• W2904186698 hasConceptScore W2904186698C2780955175 @default.
• W2904186698 hasConceptScore W2904186698C2781436528 @default.
• W2904186698 hasConceptScore W2904186698C2991743468 @default.
• W2904186698 hasConceptScore W2904186698C2993634128 @default.
• W2904186698 hasConceptScore W2904186698C42219234 @default.
• W2904186698 hasConceptScore W2904186698C44249647 @default.

• next